Effect of metformin on gut microbiota imbalance in patients with T2DM, and the value of probiotic supplementation
Main Article Content
Keywords
gut microbiota, inflammatory factors, insulin resistance, metformin, probiotics, type 2 diabetes
Abstract
Purpose: To investigate the effect of metformin on gut microbiota imbalance in patients with type 2 diabetes mellitus (T2DM), and the value of probiotic supplementation.
Methods: A total of 84 newly diagnosed T2DM patients were randomly divided into probiotics group, metformin group, and control group, with 28 patients in each group. The blood glucose control, islet function, gut microbiota, and inflammatory factors were compared between three groups.
Results: After 3 months of treatment, fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2-h PG), and glycosylated hemoglobin A1c (HbA1c) were evidently decreased in both probiotics and metformin groups (P < 0.05) and were lower than that in the control group prior to treatment. Besides, FPG, 2-h PG, and HbA1c were lower in the metformin group than that in the control group. FPG, 2-h PG, and HbA1c were further lower in the probiotic group than in the metformin group (P < 0.05). Fasting insulin (FINS) and islet β cell (HOMA-β) -function were dramatically increased in the same group (P < 0.05), while insulin-resistant islet β cells (HOMA-IR) were significantly lower in the same group (P < 0.05); FINS and HOMA-β were significantly higher, while HOMA-IR was significantly lower (P < 0.05) in both groups than in the control group prior to treatment. HOMA-IR was also lower in the probiotic group than in the metformin group after treatment (P < 0.05); the number of lactobacilli and bifidobacteria increased (P < 0.05) in both probiotic and metformin groups than in the control group prior to treatment, and the number of Enterobacteriaceae and Enterococcus was lower in the control group prior to treatment (P < 0.05). In addition, the number of lactobacilli and bifidobacteria was higher and the number of enterobacteria and enterococci was lower in the probiotic group than that in the metformin group after treatment, and the differences were statistically significant (P < 0.05). Lipopolysaccharide (LPS), interleukin 6 (IL-6), and C-reactive protein (CRP) levels were lower in both probiotic and metformin groups (P < 0.05). The serum LPS, IL-6, and CRP levels were lower in both probiotic and metformin groups, compared to the control group prior to the treatment (P < 0.05).
Conclusion: Metformin while treating T2DM assists in improving the imbalance of gut microbiota.
References
2. Daly A, Hovorka R. Technology in the management of type 2 diabetes: Present status and future prospects. Diabetes Obes Metab. 2021;23(8):1722–32. 10.1111/dom.14418
3. Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65(1):3–13. 10.1007/s00125-021-05585-2
4. Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. J Exp Clin Cancer Res. 2022;41(1):1–16. 10.1186/s13046-021-02233-w
5. Salgaço MK, Oliveira LGS, Costa GN, Bianchi F, Sivieri K. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol. 2019;103(23–24):9229–38. 10.1007/s00253-019-10156-y
6. Zheng Y, Gou X, Zhang L, Gao H, Wei Y, Yu X, et al. Interactions between gut microbiota, host, and herbal medicines: A review of new insights into the pathogenesis and treatment of type 2 diabetes. Front Cell Infect Microbiol. 2020;10:360. 10.3389/fcimb.2020.00360
7. Ardeshirlarijani E, Tabatabaei-Malazy O, Mohseni S, Qorbani M, Larijani B, Baradar Jalili R. Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: A meta-analysis of randomized trials. Daru J Fac Pharm Tehran Univ Med Sci. 2019;27(2):827–37. 10.1007/s40199-019-00302-2
8. Pryor R, Martinez-Martinez D, Quintaneiro L, Cabreiro F. The role of the microbiome in drug response. Ann Rev Pharmacol Toxicol. 2020;60:417–35. 10.1146/annurev-pharmtox-010919-023612
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med J Br Diabetic Assoc. 1998;15(7):539–53. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
10. Ashall V, Morton D, Clutton E. A declaration of Helsinki for-animals. Vet Anaesth Analg 2023;50(4):309–14. 10.1016/j.vaa.2023.03.005
11. WY Ma. L-PM, Yi B, Zhang M, Feng S-X, Tian L-P. Antidiabetic activity of Callicarpa nudiflora extract in type 2 diabetic rats via activation of the AMPK-ACC pathway. Trop J Pharm Res. 2019;009(011):456–66. 10.4103/2221-1691.270978
12. Naowaboot J, Somparn N, Saenthaweesuk S. Renoprotective effect of umbelliferone in high-fat diet/streptozotocin-induced type 2 diabetic rats. Trop J Pharm Res. 2020;010(001):11–7. 10.4103/2221-1691.273089
13. Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller III ER, et al. Metformin affects gut-microbiome composition and function and circulating short-chain fatty acids: A randomized trial. Diabetes Care. 2021;44(7):1462–71. 10.2337/dc20-2257
14. Karusheva Y, Koessler T, Strassburger K, Markgraf D, Mastrototaro L, Jelenik T, et al. Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: A randomized controlled crossover trial. Am J Clin Nutr. 2019;110(5):1098–1107. 10.1093/ajcn/nqz191
15. de Siqueira Cardinelli C, Torrinhas RS, Sala P, Pudenzi MA, Angolini CFF, da Silva MM, et al. Fecal bile acid profile after Roux-en-Y gastric bypass and its association with the remission of type 2 diabetes in obese women: A preliminary study. Clin Nutr. 2019;38(6):2906–12. 10.1016/j.clnu.2018.12.028
16. Zhao L, Lou H, Peng Y, Chen S, Fan L, Li X. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota. Diabetes Res Clin Prac. 2020;169:108418. 10.1016/j.diabres.2020.108418
17. Zhang M, Feng R, Yang M, Qian C, Wang Z, Liu W, et al. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care. 2019;7(1):e000717. 10.1136/bmjdrc-2019-000717
18. Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER, 3rd, et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: A randomized trial. Diabetes Care. 2021;44(7):1462–71. 10.2337/dc20-2257
19. Karusheva Y, Koessler T, Strassburger K, Markgraf D, Mastrototaro L, Jelenik T, et al. Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: A randomized controlled crossover trial. Am J Clin Nutr. 2019;110(5):1098–1107. 10.1093/ajcn/nqz191
20. de Siqueira Cardinelli C, Torrinhas RS, Sala P, Pudenzi MA, Fernando FAC, Marques da Silva M, et al. Fecal bile acid profile after Roux-en-Y gastric bypass and its association with the remission of type 2 diabetes in obese women: A preliminary study. Clin Nutr (Edinburgh, Scotland). 2019;38(6):2906–12. 10.1016/j.clnu.2018.12.028
21. Zhao L, Lou H, Peng Y, Chen S, Fan L, Li X. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota. Diabetes Res Clin Prac. 2020;169:108418. 10.1016/j.diabres.2020.108418
22. Seicaru EM, Popa Ilie IR, Cătinean A, Crăciun AM, Ghervan C. Enhancing metformin effects by adding gut microbiota modulators to ameliorate the metabolic status of obese, insulin-resistant hosts. J Gastrointest Liver Dis (JGLD). 2022;31(3):344–54. 10.15403/jgld-4248
23. Hata S, Nakajima H, Hashimoto Y, Miyoshi T, Hosomi Y, Okamura T, et al. Effects of probiotic Bifidobacterium bifidum G9-1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open--label, single-arm, exploratory research trial. J Diabetes Invest. 2022;13(3):489–500. 10.1111/jdi.13698
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.